melanotic macule buccal mucosa Pigmented Oral Lesions: Clues to Identifying the Potentially Malignant Oral pigmented lesions: Clinicopathologic features

When Timing May Matter Taking vitamins with meals is a practical habit that supports absorption and reduces the chance of digestive discomfort

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Szary syndrome)

After two years post-recovery, PASC continues to affect the disability-adjusted life years (DALYs per 1000 persons) of about 25.3% non-hospitalized and 21.3% hospitalized individuals 128

OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship

It activates GLP-1 receptors in the brain to reduce appetite and increase satiety

Accuracy here is key